Contributions
Abstract: P810
Type: Poster
Abstract Category: Therapy - symptomatic - 33 Treatment of specific symptoms
Introduction: Fampridine is a drug approved for the treatment of walking disability in patients with multiple sclerosis (MS). It causes an increment in the velocity of electric transmission through the demyelinated axon.
Objective: To analyze the effect of fampridine on the upper limbs motor function and quality of life.
Material and methods: Observational, prospective study of patients with MS on treatment with fampridine. Timed 25 Foot Walk (T25FW), MS Walking Scale-12 (MSWS-12), 9 Hole Peg Test (9-HPT) and EuroQol 5-Dimension (EQ-5D) were done before and 14 days after treatment start. Patients with a good response to fampridine (reduction of at least 20% in T25FW and 6 points in MSWS-12) were also evaluated at 3 and 6 months.
Results: 68 patients were included in the study. A significant improvement (p< 0.001) was obtained at day 14, month 3 and 6 in 9-HPT (dominant hand: -8.65%, -13.14% y -0.8%; non-dominant hand: -5.44%, -7.98% y -11.92%) and in the EQ-5D (20.24%, 18.93% y 47.82%). Differences in 9-HPT were correlated with the changes in T25FW (0.438, p=0.001) and in MSWS-12 (0.542, p< 0.001). However, the differences in EQ-5D were independent of the tests T25FW, 9-HPT and MSWS-12.
Conclusions: Fampridine causes an improvement of upper limbs motor function and in the quality of life. Changes in quality of life are independent of motor function, therefore it is possible that other benefits not detected with these test would happen in these patients.
Disclosure:
Lagorio AN.: Nothing to disclosure.
Costa Arpín E.: has served as speaker or consultant for Biogen Idec, Merck Serono, Bayer HealthCare, Genzyme, TEVA and UCB Pharma.
Puente Hernández M.: Nothing to disclosure.
Prieto González JM. has served as advisor, consultant and speaker for Bayer HealthCare Pharmaceuticals, Biogen Idec Inc., Genzyme Corporation, Novartis Pharmaceuticals Corporation, Sanofi Aventis and Teva Pharmaceuticals. He also has received grants for clinical research from Biogen Idec Inc and Novartis Pharmaceuticals Corporation.
Abstract: P810
Type: Poster
Abstract Category: Therapy - symptomatic - 33 Treatment of specific symptoms
Introduction: Fampridine is a drug approved for the treatment of walking disability in patients with multiple sclerosis (MS). It causes an increment in the velocity of electric transmission through the demyelinated axon.
Objective: To analyze the effect of fampridine on the upper limbs motor function and quality of life.
Material and methods: Observational, prospective study of patients with MS on treatment with fampridine. Timed 25 Foot Walk (T25FW), MS Walking Scale-12 (MSWS-12), 9 Hole Peg Test (9-HPT) and EuroQol 5-Dimension (EQ-5D) were done before and 14 days after treatment start. Patients with a good response to fampridine (reduction of at least 20% in T25FW and 6 points in MSWS-12) were also evaluated at 3 and 6 months.
Results: 68 patients were included in the study. A significant improvement (p< 0.001) was obtained at day 14, month 3 and 6 in 9-HPT (dominant hand: -8.65%, -13.14% y -0.8%; non-dominant hand: -5.44%, -7.98% y -11.92%) and in the EQ-5D (20.24%, 18.93% y 47.82%). Differences in 9-HPT were correlated with the changes in T25FW (0.438, p=0.001) and in MSWS-12 (0.542, p< 0.001). However, the differences in EQ-5D were independent of the tests T25FW, 9-HPT and MSWS-12.
Conclusions: Fampridine causes an improvement of upper limbs motor function and in the quality of life. Changes in quality of life are independent of motor function, therefore it is possible that other benefits not detected with these test would happen in these patients.
Disclosure:
Lagorio AN.: Nothing to disclosure.
Costa Arpín E.: has served as speaker or consultant for Biogen Idec, Merck Serono, Bayer HealthCare, Genzyme, TEVA and UCB Pharma.
Puente Hernández M.: Nothing to disclosure.
Prieto González JM. has served as advisor, consultant and speaker for Bayer HealthCare Pharmaceuticals, Biogen Idec Inc., Genzyme Corporation, Novartis Pharmaceuticals Corporation, Sanofi Aventis and Teva Pharmaceuticals. He also has received grants for clinical research from Biogen Idec Inc and Novartis Pharmaceuticals Corporation.